Impact of insulin sensitizers on the incidence of dementia: A meta-analysis

Dementia and Geriatric Cognitive Disorders

Volumn 41, Issue 5-6, 2016, Pages 251-260

  Ye, Fang ^a   Luo, Yong Jie ^a   Xiao, Jun ^a   Yu, Neng Wei ^a   Yi, Gang ^a  

^a SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Dementia; Diabetes mellitus; Insulin sensitizer; Metformin; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; INSULIN SENSITIZING AGENT; METFORMIN; ANTIDIABETIC AGENT;

ARTICLE; DEMENTIA; DISEASE ASSOCIATION; EMBASE; HUMAN; INCIDENCE; MEDLINE; META ANALYSIS; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK FACTOR; WEB OF SCIENCE; AGED; INSULIN RESISTANCE; PHYSIOLOGY;

AGED; DEMENTIA; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; METFORMIN; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 84982274145     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000445941     Document Type: Article

References (28)

1. WHO: Dementia Fact sheet No. 362. http://www.who.int/mediacentre/factsheets/fs362/en/ (accessed December 28, 2015).
2. Cheung SL, Yip SF, Branch LG, Robine JM: Decreased proportion of dementia-free life expectancy in Hong Kong SAR. Dement Geriatr Cogn Disord 2015; 40: 72-84.
3. Burns A, Iliffe S: Dementia. BMJ 2009; 338:b75.
4. O'Caoimh R, Kehoe PG, Molloy DW: Renin angio-tensin aldosterone system inhibition in controlling dementiarelated cognitive decline. J Alzheimers Dis 2014; 42(suppl 4):575-586.
5. Lista S, Dubois B, Hampel H: Paths to Alzheimers disease prevention: from modifiable risk factors to biomarker enrichment strategies. J Nutr Health Aging 2015; 19: 154-163.
6. Ojo O, Brooke J: Evaluating the association between diabetes, cognitive decline and dementia. Int J Environ Res Public Health 2015; 12: 8281-8294.
7. Carlsson CM: Type 2 diabetes mellitus, dyslipidaemia, and Alzheimers disease. J Alzheimers Dis 2010; 20: 711-722.
8. Wu Q, Tchetgen Tchetgen EJ, Osypuk T, Weuve J, White K, Mujahid M, Glymour MM: Estimating the cognitive effects of prevalent diabetes, recent onset diabetes, and the duration of diabetes among older adults. Dement Geriatr Cogn Disord 2015; 39: 239-249.
9. Lu FP, Lin KP, Kuo HK: Diabetes and the risk of multi-system aging phenotypes: a systematic review and metaanalysis. PLoS One 2009; 4:e4144.
10. Ritchie K, Carrire I, Ritchie CW, Berr C, Artero S, Ancelin ML: Designing prevention programmes to reduce incidence of dementia: prospective cohort study of modifiable risk factors. BMJ 2010; 341:c5241.
11. Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H: Summary of the evidence on modifiable risk factors for cognitive decline and dementia: a population-based perspective. Alzheimers Dement 2015; 11: 718-726.
12. Umegaki H, Hayashi T, Nomura H, Yanagawa M, Nogogaki Z, Nakshima H, Kuzuya M:Cognitive dysfunction: an emerging concept of a new diabetic complication in the elderly. Geriatr Gerontol Int 2013; 13: 28-34.
13. Cholerton B, Baker LD, Craft S: Insulin resistance and pathological brain ageing. Diabet Med 2011; 28: 1463-1475.
14. Verdile G, Fuller SJ, Martins RN: The role of type 2 diabetes in neurodegeneration. Neurobiol Dis 2015; 84: 22-38.
15. Ma L, Wang J, Li Y: Insulin resistance and cognitive dysfunction. Clin Chim Acta 2015; 444: 18-23.
16. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
17. Altman DG, Bland JM: Interaction revisited: the difference between two estimates. BMJ 2003; 326: 219.
18. Heneka MT, Fink A, Doblhammer G: Effect of pioglitazone medication on the incidence of dementia. Ann Neurol 2015; 78: 284-294.
19. Cheng C, Lin CH, Tsai YW, Tsai CJ, Chou PH, Lan TH: Type 2 diabetes and antidiabetic medications in relation to dementia diagnosis. J Gerontol A Biol Sci Med Sci 2014; 69: 1299-1305.
20. Ng TP, Feng L, Yap KB, Lee TS, Tan CH, Winblad B: Long-term metformin usage and cognitive function among older adults with diabetes. J Alzheimers Dis 2014; 41: 61-68.
21. Huang CC, Chung CM, Leu HB, Lin LY, Chiu CC, Hsu CY, et al. Diabetes mellitus and the risk of Alzheimers disease: a nationwide population-based study. PLoS One 2014; 9:e87095.
22. Imfeld P, Bodmer M, Jick SS, Meier CR: Metformin, other antidiabetic drugs, and risk of Alzheimers disease: a population-based case-control study. J Am Geriatr Soc 2012; 60: 916-921.
23. Hsu CC, Wahlqvist ML, Lee MS, Tsai HN: Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. J Alzheimers Dis 2011; 24: 485-493.
24. Rizzo MR, Barbieri M, Boccardi V, Angellotti E, Marfella R, Paolisso G: Dipeptidyl peptidase-4 inhibitors have protective effect on cognitive impairment in aged diabetic patients with mild cognitive impairment. J Gerontol A Biol Sci Med Sci 2014; 69: 1122-1131.
25. Ritchie K, Carrire I, Ritchie CW, Berr C, Artero S, Ancelin ML: Designing prevention programmes to reduce incidence of dementia: prospective cohort study of modifiable risk factors. BMJ 2010; 341:c3885.
26. Ryan CM, Freed MI, Rood JA, Cobitz AR, Waterhouse BR, Strachan MW: Improving metabolic control leads to better working memory in adults with type 2 diabetes. Diabetes Care 2006; 29: 345-351.
27. Guo M, Mi J, Jiang QM, Xu JM, Tang YY, Tian G, Wang B: Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus. Clin Exp Pharmacol Physiol 2014; 41: 650-656.
28. Abbatecola AM, Lattanzio F, Molinari AM, Cioffi M, Mansi L, Rambaldi P, DiCioccio L, Cacciapuoti F, Canonico R, Paolisso G: Rosiglitazone and cognitive stability in older individuals with type 2 diabetes and mild cognitive impairment. Diabetes Care 2010; 33: 1706-1711.